A phase II study of vorinostat (<scp>MK</scp>‐0683) in patients with polycythaemia vera and essential thrombocythaemiaChristen Lykkegaard Andersen, Hans Carl Hasselbalch, Mary Frances McMullin et al.|British Journal of Haematology|2013Cited by 71
Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasmsJohanna Abelsson, Peter Johansson, Robyn M. Emanuel et al.|Leukemia & lymphoma/Leukemia and lymphoma|2013Cited by 55
Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study GroupGunnar Birgegård, Björn Andréasson, Jan Samuelsson et al.|European Journal Of Haematology|2018Cited by 37
Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-upElisabeth Ejerblad, Gunnar Birgegård, Hans Michael Kvasnicka et al.|Hematology|2012Cited by 30
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostatChristen Lykkegaard Andersen, Hans Carl Hasselbalch, Mads Emil Bjørn et al.|Leukemia Research|2014Cited by 13